$RMD
RESMED INC

2021 Q3 Form 10-Q Financial Statement

#000094381921000031 Filed on October 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $904.0M $751.9M $770.3M
YoY Change 20.22% 10.4% 9.26%
Cost Of Revenue $397.7M $313.3M $321.0M
YoY Change 26.95% 8.24% 6.12%
Gross Profit $506.3M $438.7M $449.4M
YoY Change 15.42% 12.01% 11.68%
Gross Profit Margin 56.0% 58.34% 58.34%
Selling, General & Admin $176.7M $159.0M $165.4M
YoY Change 11.15% -5.05% -3.61%
% of Gross Profit 34.9% 36.24% 36.8%
Research & Development $59.95M $54.53M $52.50M
YoY Change 9.93% 13.53% 2.74%
% of Gross Profit 11.84% 12.43% 11.68%
Depreciation & Amortization $39.10M $39.47M $38.60M
YoY Change -0.92% 3.98% -9.39%
% of Gross Profit 7.72% 9.0% 8.59%
Operating Expenses $244.4M $221.8M $226.1M
YoY Change 10.2% 0.57% -2.04%
Operating Profit $261.9M $216.9M $223.3M
YoY Change 20.76% 26.76% 30.13%
Interest Expense $5.360M $6.725M -$14.90M
YoY Change -20.3% -38.82% -20.32%
% of Operating Profit 2.05% 3.1% -6.67%
Other Income/Expense, Net -$3.125M -$1.042M $3.800M
YoY Change 199.9% -94.92% -157.58%
Pretax Income $258.8M $215.9M $212.1M
YoY Change 19.89% 43.34% 121.4%
Income Tax $55.18M $37.48M $34.30M
% Of Pretax Income 21.32% 17.36% 16.17%
Net Earnings $203.6M $178.4M $177.8M
YoY Change 14.15% 48.46% 158.43%
Net Earnings / Revenue 22.52% 23.72% 23.08%
Basic Earnings Per Share $1.40 $1.23
Diluted Earnings Per Share $1.39 $1.22 $1.217M
COMMON SHARES
Basic Shares Outstanding 145.7M 144.9M 144.7M
Diluted Shares Outstanding 146.9M 146.1M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $276.1M $421.4M $463.2M
YoY Change -34.47% 144.72% 214.89%
Cash & Equivalents $276.1M $421.4M $463.2M
Short-Term Investments
Other Short-Term Assets $202.1M $168.7M $159.3M
YoY Change 19.8% 30.27% 44.42%
Inventory $506.6M $478.0M $416.9M
Prepaid Expenses
Receivables $575.6M $464.9M $474.6M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.586B $1.543B $1.523B
YoY Change 2.83% 32.86% 33.01%
LONG-TERM ASSETS
Property, Plant & Equipment $467.3M $424.8M $417.3M
YoY Change 10.01% 10.93% 7.71%
Goodwill $1.922B $1.900B $1.890B
YoY Change 1.17% 2.33% 1.82%
Intangibles
YoY Change
Long-Term Investments $15.77M $18.07M $14.11M
YoY Change -12.74% -60.2% -34.88%
Other Assets $163.0M $145.5M $148.7M
YoY Change 12.01% 2.96% -1.52%
Total Long-Term Assets $3.143B $3.078B $3.064B
YoY Change 2.1% 2.83% 3.43%
TOTAL ASSETS
Total Short-Term Assets $1.586B $1.543B $1.523B
Total Long-Term Assets $3.143B $3.078B $3.064B
Total Assets $4.729B $4.621B $4.587B
YoY Change 2.34% 11.22% 11.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $173.7M $117.6M $135.8M
YoY Change 47.71% 7.15% 17.34%
Accrued Expenses $274.1M $269.9M $270.4M
YoY Change 1.57% 16.69% 1.5%
Deferred Revenue $112.5M $102.0M $98.62M
YoY Change 10.28% 17.34% 11.22%
Short-Term Debt $12.00M $11.99M $11.99M
YoY Change 0.1% -0.03% -0.04%
Long-Term Debt Due $12.00M $12.00M $12.00M
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $624.2M $590.9M $602.8M
YoY Change 5.64% 7.34% 8.41%
LONG-TERM LIABILITIES
Long-Term Debt $793.7M $1.044B $1.164B
YoY Change -24.01% -13.56% -7.53%
Other Long-Term Liabilities $5.981M $8.568M $8.347M
YoY Change -30.19% 318.56% 305.59%
Total Long-Term Liabilities $1.079B $1.351B $1.488B
YoY Change -20.14% -9.13% 0.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $624.2M $590.9M $602.8M
Total Long-Term Liabilities $1.079B $1.351B $1.488B
Total Liabilities $1.703B $1.942B $2.090B
YoY Change -12.3% -4.68% 2.7%
SHAREHOLDERS EQUITY
Retained Earnings $3.222B $2.954B $2.833B
YoY Change 9.09% 18.12% 16.28%
Common Stock $1.644B $1.588B $1.571B
YoY Change 3.5% 3.79% 3.92%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.623B $1.623B $1.623B
YoY Change 0.0% 0.0% 0.0%
Treasury Stock Shares $41.84M $41.84M $41.84M
Shareholders Equity $3.026B $2.679B $2.497B
YoY Change
Total Liabilities & Shareholders Equity $4.729B $4.621B $4.587B
YoY Change 2.34% 11.22% 11.68%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income $203.6M $178.4M $177.8M
YoY Change 14.15% 48.46% 158.43%
Depreciation, Depletion And Amortization $39.10M $39.47M $38.60M
YoY Change -0.92% 3.98% -9.39%
Cash From Operating Activities -$65.66M $144.0M $330.3M
YoY Change -145.6% -11.31% 132.77%
INVESTING ACTIVITIES
Capital Expenditures $27.34M $13.50M -$21.10M
YoY Change 102.5% -40.45% -12.81%
Acquisitions $0.00
YoY Change
Other Investing Activities -$10.08M -$3.400M $17.80M
YoY Change 196.5% -60.0% -190.82%
Cash From Investing Activities -$41.87M -$22.11M -$3.400M
YoY Change 89.39% -33.45% -92.26%
FINANCING ACTIVITIES
Cash Dividend Paid $61.19M $56.51M
YoY Change 8.28% 0.82%
Common Stock Issuance & Retirement, Net $4.354M $1.026M
YoY Change 324.37% -81.71%
Debt Paid & Issued, Net $0.00 $175.0M
YoY Change -100.0% -71.5%
Cash From Financing Activities 92.97M -175.3M -236.4M
YoY Change -153.05% 75.13% 142.21%
NET CHANGE
Cash From Operating Activities -65.66M 144.0M 330.3M
Cash From Investing Activities -41.87M -22.11M -3.400M
Cash From Financing Activities 92.97M -175.3M -236.4M
Net Change In Cash -19.13M -41.74M 90.50M
YoY Change -54.17% -266.79% 22525.0%
FREE CASH FLOW
Cash From Operating Activities -$65.66M $144.0M $330.3M
Capital Expenditures $27.34M $13.50M -$21.10M
Free Cash Flow -$93.00M $130.5M $351.4M
YoY Change -171.26% -6.58% 111.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 dei Amendment Flag
AmendmentFlag
false
CY2021Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2021Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q3 dei Entity Address Country
EntityAddressCountry
US
CY2021Q3 dei Entity Central Index Key
EntityCentralIndexKey
0000943819
CY2021Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q3 rmd Reclassifications In Equity Investments
ReclassificationsInEquityInvestments
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 dei Document Type
DocumentType
10-Q
CY2021Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q3 dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2021Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q3 dei Entity File Number
EntityFileNumber
001-15317
CY2021Q3 dei Entity Registrant Name
EntityRegistrantName
ResMed Inc.
CY2021Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0152841
CY2021Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
9001 Spectrum Center Blvd.
CY2021Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92123
CY2021Q3 dei City Area Code
CityAreaCode
858
CY2021Q3 dei Local Phone Number
LocalPhoneNumber
836-5000
CY2021Q3 dei Security12b Title
Security12bTitle
Common Stock, par value $0.004 per share
CY2021Q3 dei Trading Symbol
TradingSymbol
RMD
CY2021Q3 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q3 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q3 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q3 dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
173696000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
138008000
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
3142912000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
274106000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320599000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22919000
CY2021Q2 us-gaap Goodwill
Goodwill
1927901000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
375400000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
392582000
CY2021Q3 us-gaap Deferred Income Taxes And Other Assets Noncurrent
DeferredIncomeTaxesAndOtherAssetsNoncurrent
80765000
CY2021Q2 us-gaap Deferred Income Taxes And Other Assets Noncurrent
DeferredIncomeTaxesAndOtherAssetsNoncurrent
79904000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
162991000
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
3153368000
CY2021Q3 us-gaap Assets
Assets
4729167000
CY2021Q2 us-gaap Assets
Assets
4728125000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
160916000
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
145723142
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
276149000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
295278000
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
29917000
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
32138000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
575554000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
614292000
CY2021Q3 us-gaap Inventory Net
InventoryNet
506644000
CY2021Q2 us-gaap Inventory Net
InventoryNet
457033000
CY2021Q3 us-gaap Prepaid Taxes
PrepaidTaxes
77826000
CY2021Q2 us-gaap Prepaid Taxes
PrepaidTaxes
72409000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
150082000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
135745000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
1586255000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
1574757000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
467344000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
463490000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
134375000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
128575000
CY2021Q3 us-gaap Goodwill
Goodwill
1922037000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23585000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
112528000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
109611000
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
28909000
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
307963000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
187547442
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145648358
CY2021Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
12000000
CY2021Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
12000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.004
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
583000
CY2021Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
583000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1643661000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1622199000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3222064000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
624158000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
911766000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
93255000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
91496000
CY2021Q3 us-gaap Deferred Income Taxes And Other Tax Liabilities Noncurrent
DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
11294000
CY2021Q2 us-gaap Deferred Income Taxes And Other Tax Liabilities Noncurrent
DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
11319000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
121518000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
114779000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5981000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6802000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
793668000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
643351000
CY2021Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
53244000
CY2021Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
62933000
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1078960000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
930680000
CY2021Q3 us-gaap Liabilities
Liabilities
1703118000
CY2021Q2 us-gaap Liabilities
Liabilities
1842446000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.004
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145711208
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
187484592
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
3079640000
CY2021Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
41836234
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
41836234
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1623256000
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
1623256000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-217003000
CY2021Q3 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
5612000
CY2020Q3 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
8476000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-193487000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3026049000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
216896000
CY2021Q3 us-gaap Interest Expense
InterestExpense
5360000
CY2020Q3 us-gaap Interest Expense
InterestExpense
6725000
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1386000
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2288000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2885679000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4729167000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4728125000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
904015000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
751944000
CY2021Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
386667000
CY2020Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
301304000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11059000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11979000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
397726000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
313283000
CY2021Q3 us-gaap Gross Profit
GrossProfit
506289000
CY2020Q3 us-gaap Gross Profit
GrossProfit
438661000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
176719000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
158989000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59950000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54533000
CY2021Q3 rmd Amortization Of Acquired Intangible Assets1
AmortizationOfAcquiredIntangibleAssets1
7707000
CY2020Q3 rmd Amortization Of Acquired Intangible Assets1
AmortizationOfAcquiredIntangibleAssets1
8243000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
244376000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
221765000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
261913000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1991000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-505000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3125000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1042000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
258788000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
215854000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
55175000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37482000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
203613000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
178372000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.40
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.23
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.39
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.22
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.42
CY2020Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.39
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145680000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144900000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146860000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146100000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
203613000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
178372000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-23516000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
43791000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
180097000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
222163000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2885679000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4354000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-195000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
17303000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-23516000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
203613000
CY2021Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.42
CY2021Q3 us-gaap Dividends
Dividends
61189000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
3026049000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
2497027000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1026000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
227000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
16071000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
43791000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
178372000
CY2020Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.39
CY2020Q3 us-gaap Dividends
Dividends
56511000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2678860000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
203613000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
178372000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39102000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39466000
CY2021Q3 rmd Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
8517000
CY2020Q3 rmd Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
10422000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
17303000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
16071000
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1386000
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2288000
CY2021Q3 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
5612000
CY2020Q3 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
8476000
CY2021Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-33704000
CY2020Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16110000
CY2021Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55976000
CY2020Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
52396000
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14391000
CY2020Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3415000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-293303000
CY2020Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-61273000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65657000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
143999000
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27340000
CY2020Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13501000
CY2021Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4453000
CY2020Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5237000
CY2021Q3 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6600000
CY2020Q3 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8196000
CY2021Q3 us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
3481000
CY2020Q3 us-gaap Payments For Proceeds From Derivative Instrument Investing Activities
PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
-4824000
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41874000
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22110000
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4354000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1026000
CY2021Q3 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
-195000
CY2020Q3 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
227000
CY2021Q3 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
150000000
CY2020Q3 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
55000000
CY2020Q3 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
175000000
CY2021Q3 us-gaap Payments Of Dividends
PaymentsOfDividends
61189000
CY2020Q3 us-gaap Payments Of Dividends
PaymentsOfDividends
56511000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
92970000
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-175258000
CY2021Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-4568000
CY2020Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
11627000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19129000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41742000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
295278000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
463156000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
276149000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
421414000
CY2021Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
345909000
CY2020Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
51370000
CY2021Q3 us-gaap Interest Paid Net
InterestPaidNet
5360000
CY2020Q3 us-gaap Interest Paid Net
InterestPaidNet
6842000
CY2021Q3 rmd Organization And Basis Of Presentation Policy Text Bock
OrganizationAndBasisOfPresentationPolicyTextBock
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Organization and Basis of Presentation</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (“SaaS”) business in the United States that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The condensed consolidated financial statements for the three months ended September 30, 2021 and September 30, 2020 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K (our “Form 10-K”) for the year ended June 30, 2021.</span>
CY2021Q3 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q3 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
4087000
CY2020Q3 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
1960000
CY2021Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
25157000
CY2020Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
24779000
CY2021Q3 rmd Lessor Lease Revenue
LessorLeaseRevenue
29244000
CY2020Q3 rmd Lessor Lease Revenue
LessorLeaseRevenue
26739000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
467344000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
463490000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
375400000
CY2021Q3 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
904015000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
751944000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39102000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39466000
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
220784000
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
155419000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3494000
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4647000
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
282366000
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
296967000
CY2021Q3 us-gaap Inventory Net
InventoryNet
506644000
CY2021Q2 us-gaap Inventory Net
InventoryNet
457033000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1084064000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1085629000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
616720000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
622139000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
392582000
CY2021Q2 us-gaap Goodwill
Goodwill
1927901000
CY2021Q3 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-5864000
CY2021Q3 us-gaap Goodwill
Goodwill
1922037000
CY2021Q3 rmd Marketable Equity Investments Fair Value
MarketableEquityInvestmentsFairValue
33138000
CY2021Q2 rmd Marketable Equity Investments Fair Value
MarketableEquityInvestmentsFairValue
29084000
CY2021Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
31160000
CY2021Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
23002000
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
15768000
CY2021Q2 us-gaap Equity Method Investments
EquityMethodInvestments
17154000
CY2021Q3 rmd Equity Investments Total By Measurement Category
EquityInvestmentsTotalByMeasurementCategory
80066000
CY2021Q2 rmd Equity Investments Total By Measurement Category
EquityInvestmentsTotalByMeasurementCategory
69240000
CY2021Q2 rmd Equity Investments
EquityInvestments
69240000
CY2021Q3 rmd Additional Equity Investments
AdditionalEquityInvestments
6600000
CY2021Q3 rmd Observable Price Adjustments On Non Marketable Equity Securities
ObservablePriceAdjustmentsOnNonMarketableEquitySecurities
5367000
CY2021Q3 rmd Ongoing Mark To Market Adjustments On Marketable Equity Securities
OngoingMarkToMarketAdjustmentsOnMarketableEquitySecurities
454000
CY2021Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
209000
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1386000
CY2021Q3 rmd Equity Investments
EquityInvestments
80066000
CY2020Q2 rmd Equity Investments
EquityInvestments
44142000
CY2020Q3 rmd Additional Equity Investments
AdditionalEquityInvestments
8196000
CY2020Q3 rmd Ongoing Mark To Market Adjustments On Marketable Equity Securities
OngoingMarkToMarketAdjustmentsOnMarketableEquitySecurities
8476000
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2288000
CY2020Q3 rmd Equity Investments
EquityInvestments
58526000
CY2021Q3 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
5600000
CY2020Q3 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
8500000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-14100000
CY2021Q3 us-gaap Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
4100000
CY2021Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
22032000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
21132000
CY2021Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
5413000
CY2020Q3 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
5347000
CY2021Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
3972000
CY2020Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
3428000
CY2021Q3 us-gaap Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss
StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss
513000
CY2020Q3 us-gaap Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss
StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss
-640000
CY2021Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
22960000
CY2020Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
23691000
CY2021Q3 rmd Short Term Borrowings Gross
ShortTermBorrowingsGross
12000000
CY2021Q2 rmd Short Term Borrowings Gross
ShortTermBorrowingsGross
12000000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
796000000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
646000000
CY2021Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2332000
CY2021Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2649000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
793668000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
643351000
CY2021Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
805668000
CY2021Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
655351000
CY2021Q3 rmd Debt To Consolidated Ebitda Ratio
DebtToConsolidatedEbitdaRatio
3.50
CY2021Q3 rmd Line Of Credit Facility Collateral Percentage Of Company
LineOfCreditFacilityCollateralPercentageOfCompany
0.10
CY2021Q3 us-gaap Senior Notes
SeniorNotes
500000000.0
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1322000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
109475000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
203613000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
178372000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145680000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144900000
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1180000
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1200000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146860000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146100000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.40
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.23
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.39
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.22

Files In Submission

Name View Source Status
0000943819-21-000031-index-headers.html Edgar Link pending
0000943819-21-000031-index.html Edgar Link pending
0000943819-21-000031.txt Edgar Link pending
0000943819-21-000031-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rmd-20210930.xsd Edgar Link pending
rmd-20210930x10q.htm Edgar Link pending
rmd-20210930x10q_htm.xml Edgar Link completed
rmd-20210930xex31_1.htm Edgar Link pending
rmd-20210930xex31_2.htm Edgar Link pending
rmd-20210930xex32.htm Edgar Link pending
rmd-20210930_cal.xml Edgar Link unprocessable
rmd-20210930_def.xml Edgar Link unprocessable
rmd-20210930_lab.xml Edgar Link unprocessable
rmd-20210930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending